Norges Bank bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,228,939 shares of the company’s stock, valued at approximately $56,703,000.
A number of other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in Vaxcyte by 30.6% in the third quarter. JPMorgan Chase & Co. now owns 1,565,036 shares of the company’s stock valued at $56,373,000 after buying an additional 366,266 shares in the last quarter. Pivotal bioVenture Partners Investment Advisor LLC lifted its holdings in Vaxcyte by 5.2% during the 3rd quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 1,372,425 shares of the company’s stock worth $49,435,000 after buying an additional 67,300 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in shares of Vaxcyte by 21.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 3,732,715 shares of the company’s stock worth $134,452,000 after acquiring an additional 663,817 shares in the last quarter. HighVista Strategies LLC increased its holdings in shares of Vaxcyte by 159.4% in the 3rd quarter. HighVista Strategies LLC now owns 86,802 shares of the company’s stock valued at $3,127,000 after acquiring an additional 53,345 shares during the last quarter. Finally, Bridgefront Capital LLC increased its holdings in shares of Vaxcyte by 127.2% in the 3rd quarter. Bridgefront Capital LLC now owns 24,325 shares of the company’s stock valued at $876,000 after acquiring an additional 13,617 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on PCVX shares. Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. BTIG Research increased their price target on shares of Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Wednesday, April 8th. Finally, Wall Street Zen downgraded shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Vaxcyte presently has a consensus rating of “Moderate Buy” and an average price target of $86.00.
Insider Activity at Vaxcyte
In other news, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $49.52, for a total transaction of $111,420.00. Following the transaction, the chief operating officer directly owned 158,494 shares in the company, valued at $7,848,622.88. The trade was a 1.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Elvia Cowan sold 3,000 shares of the stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $60.00, for a total value of $180,000.00. Following the transaction, the chief accounting officer directly owned 28,975 shares of the company’s stock, valued at approximately $1,738,500. This trade represents a 9.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 19,287 shares of company stock valued at $1,106,319. 3.30% of the stock is owned by company insiders.
Vaxcyte Stock Performance
PCVX opened at $47.36 on Monday. Vaxcyte, Inc. has a one year low of $29.08 and a one year high of $65.00. The stock has a market capitalization of $6.84 billion, a P/E ratio of -6.88 and a beta of 1.24. The business’s 50-day simple moving average is $55.20 and its 200-day simple moving average is $52.75.
Vaxcyte (NASDAQ:PCVX – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same quarter in the previous year, the business earned ($1.04) earnings per share. On average, equities research analysts forecast that Vaxcyte, Inc. will post -7.56 EPS for the current fiscal year.
Vaxcyte Company Profile
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
Featured Stories
- Five stocks we like better than Vaxcyte
- These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVX – Free Report).
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.
